<DOC>
	<DOCNO>NCT00116129</DOCNO>
	<brief_summary>This 24-week , randomize , double-blind , placebo-controlled , trial evaluate safety , tolerability efficacy orally administer growth hormone stimulate drug , ( code name MK-0677 ) treatment female subject primary fibromyalgia . The basis study observation many fibromyalgia patient growth hormone deficient ; early study injectable growth hormone show benefit population fibromyalgia patient .</brief_summary>
	<brief_title>Efficacy Safety Oral Growth Hormone Drug Treatment Fibromyalgia</brief_title>
	<detailed_description>This study examine whether MK-0677 treatment improve symptom fibromyalgia ( FM ) . The rationale study observation many fibromyalgia patient growth hormone deficient term low level IGF-1 , improve IGF-1 level growth hormone injection show improve fibromyalgia symptom . MK-0677 orally administer growth hormone secretagogue manufacture Merck &amp; Co. , Inc. act growth hormone secretagogue receptor anterior pituitary stimulate release growth hormone . This pathway represent additional regulation growth hormone release pituitary somatotrophs mediate growth hormone release hormone ( stimulate ) somatostatin ( inhibitory ) . Both stimulatory pathway lead pulsatile release growth hormone , approximately 4 hour interval peak level . This growth hormone secretion lead rapid robust regulation IGF-1 level 50 100 % maintain chronic therapy dose 25 mg/day . The primary aim study : 1 . To evaluate efficacy MK-0677 25 mg primary fibromyalgia subject 24-week treatment period , assess FIQ . 2 . To evaluate safety tolerability MK-0677 25 mg subject fibromyalgia . The secondary aim study determine whether : 1 . MK-0677 25 mg superior placebo reduce muscle tenderness , assess Fibromyalgia Myalgic Score ( FMyS ) . 2 . MK-0677 25 mg superior placebo improve subject ' global perception change fibromyalgia symptom , assessed Subjects ' Global Impression Change Questionnaire ( PGIC ) . 3 . MK-0677 25 mg superior placebo improve subject ' quality life , assess Quality Life Questionnaire ( QOL ) .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Subjects female primary fibromyalgia subject 30 65 year age , inclusive , low age adjust serum IGF1 level . All subject fulfill diagnosis fibromyalgia accord classification criterion American College Rheumatology ( ACR ) . All subject initial Fibromyalgia Impact Questionnaire ( FIQ ) score ≥ 40 . If subject childbearing potential sexually active , agree use effective barrier appropriate oral contraception study . Subjects take oral contraceptive must do least 2 month prior enter study . Subject pregnant nursing . Patient normal screen breast exam . If screen breast exam abnormal , suggestive breast cancer , patient must normal mammogram within last 6 month . Subject normal screen stool hemoccult . If screening stool hemoccult abnormal , likely due hemorrhoid , subject must normal sigmoidoscopy within last 2 year . Subject willing discontinue use grapefruit juice duration study . Subject willing follow telephone contact 3 month discontinue study complete return Fibromyalgia Impact Questionnaire , Patient Global Change score , Quality Life score , Brief Pain Inventory Beck Depression Questionnaire . Subject anongoing , unresolved disability litigation . Subject diabetes significantly elevate random glucose Screening visit . Subject current past history cardiovascular , pulmonary , neurological , endocrine renal disease would preclude involvement exercise program ( specifically hypertension , myocardial infarction within last 6 month , chronic obstructive pulmonary disease [ COPD ] , asthma , untreated hypothyroidism , severe depression suicide risk , previous pituitary disease surgery ) . Subject history angina congestive heart failure symptom occur rest . Subject history current evidence psychotic disorder ( e.g . schizophrenia ) , bipolar disorder major depression , substance abuse DSMIV criterion ; severe depression , evidence Beck Depression score ≥ 30 . Subject history neurological disorder fibromyalgia ( e.g . epilepsy , stroke , neuropathy , neuropathic pain ) . Subject ongoing symptom carpal tunnel syndrome . Subject significant pain state , i.e . subject must primary fibromyalgia . Subject history hepatitis liver disease active within past 12 week . Subject cancer history cancer within past 2 year , history cancer 2 year ago deem cured , subject ANY history breast cancer . ( NOTE : Subjects history basal cell squamous cell carcinoma skin treat 1 year ago evidence recurrence may participate . ) Subject abnormal thyroid stimulatinghormone , T4 concentration . Subject plan elective surgery study period . Subject history hypersensitivity idiosyncratic reaction 2 drug class ( chemical classification ) . Subject abnormal Screening visit laboratory value . Subject use follow medication : heparin , ticlopidine , ginko ( subject take warfarin ) , oral steroid ( &gt; /= 7 day per month ) , chronic use strong CYP3A4 inhibitor ( HIV protease inhibitor , macrolide antibiotic nefazodone ) , chronic use CYP3A4 inducer ( carbamazepine , phenytoin , rifampin , St. John 's Wort ) . p. Subject receive investigational drug device within 30 day study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Treatment</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>IGF-1</keyword>
	<keyword>MK-0677</keyword>
	<keyword>Oral growth hormone secretagogue</keyword>
</DOC>